Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Recruiting now

Conditions studied: Renal Cell Carcinoma

In brief

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.

Key facts

Study ID

NCT07018037

Run by

Regina Elena Cancer Institute

People needed

20

Starts

2025-01-29

Expected to finish

2027-01-29

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients over 18 years of age;
• Histological diagnosis of clear cell renal cell carcinoma;
• Evidence of advanced or metastatic disease;
• Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);
• Patients able to comply with the study procedures.
• Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.

You may not qualify if…

• Previous neoplasms;
• Previous antineoplastic treatments;
• Previous steroid treatments;
• Active viral infections (e.g., HCV, HIV, etc.);
• Lack of autonomy in adhering to study procedures.

Where it is running

• "Regina Elena" National Cancer Institute — Rome, Rome, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.